162 related articles for article (PubMed ID: 38658742)
1. Synthesis and molecular docking studies of new aryl imeglimin derivatives as a potent antidiabetic agent in a diabetic zebrafish model.
Khodakhah A; Mohammadi H; Abdoli S; Zarei I; Palimi M; Ekhtiari Z; Talebi M; Biglar M; Khorramizadeh MR; Amanlou M
Sci Rep; 2024 Apr; 14(1):9410. PubMed ID: 38658742
[TBL] [Abstract][Full Text] [Related]
2. A review of phenformin, metformin, and imeglimin.
Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
[TBL] [Abstract][Full Text] [Related]
3. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 1,3,5-triazine derivatives as an antidiabetic agent in Wistar rats via inhibition of DPP-4.
Gupta A; Bhat HR; Singh UP
Future Med Chem; 2023 May; 15(10):829-852. PubMed ID: 37307171
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
J Diabetes Res; 2020; 2020():8768954. PubMed ID: 32215274
[TBL] [Abstract][Full Text] [Related]
7. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Vuylsteke V; Chastain LM; Maggu GA; Brown C
Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
[TBL] [Abstract][Full Text] [Related]
8. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
Li Y; Lou N; Liu X; Zhuang X; Chen S
Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking, Synthesis and Biological Evaluation of Sulphonylureas/ Guanidine Derivatives as Promising Antidiabetic Agent.
Panchal II; Sen DJ; Patel AD; Shah U; Patel M; Navale A; Bhavsar V
Curr Drug Discov Technol; 2018; 15(4):315-325. PubMed ID: 28969569
[TBL] [Abstract][Full Text] [Related]
10. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
[TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
Nishiyama K; Ono M; Tsuno T; Inoue R; Fukunaka A; Okuyama T; Kyohara M; Togashi Y; Fukushima S; Atsumi T; Sato A; Tsurumoto A; Sakai C; Fujitani Y; Terauchi Y; Ito S; Shirakawa J
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37314160
[TBL] [Abstract][Full Text] [Related]
12. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
13. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
14. [Imeglimin: features of the mechanism of action and potential benefits].
Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
16. New Biguanides as Anti-Diabetic Agents, Part II: Synthesis and Anti-Diabetic Properties Evaluation of 1-Arylamidebiguanide Derivatives as Agents of Insulin Resistant Type II Diabetes.
Basyouni WM; Abbas SY; El Shehry MF; El-Bayouki KAM; Aly HF; Arafa A; Soliman MS
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027251
[TBL] [Abstract][Full Text] [Related]
17. Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P; Vial G; Fontaine E; Monternier PA; Fouqueray P; Bolze S; Moller DE; Hallakou-Bozec S
Physiol Rep; 2022 Mar; 10(5):e15151. PubMed ID: 35274817
[TBL] [Abstract][Full Text] [Related]
18. Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.
Sanada J; Obata A; Fushimi Y; Kimura T; Shimoda M; Ikeda T; Nogami Y; Obata Y; Yamasaki Y; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2022 Aug; 12(1):13220. PubMed ID: 35918386
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Biological Properties of Imeglimin Hydrochlo ride, A Novel Antidiabetic Agent: A Systematic Review.
Sultan J; Agarwal N; Sharma S
Curr Diabetes Rev; 2024; 20(5):e171023222286. PubMed ID: 37855361
[TBL] [Abstract][Full Text] [Related]
20. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
Nowak M; Grzeszczak W
Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
